ATE389388T1 - Zusammensetzungen mit verzoegerter freisetzung und verfahren zu deren herstellung - Google Patents

Zusammensetzungen mit verzoegerter freisetzung und verfahren zu deren herstellung

Info

Publication number
ATE389388T1
ATE389388T1 AT98921551T AT98921551T ATE389388T1 AT E389388 T1 ATE389388 T1 AT E389388T1 AT 98921551 T AT98921551 T AT 98921551T AT 98921551 T AT98921551 T AT 98921551T AT E389388 T1 ATE389388 T1 AT E389388T1
Authority
AT
Austria
Prior art keywords
production
sustained release
release compositions
compositions
sustained
Prior art date
Application number
AT98921551T
Other languages
English (en)
Inventor
Marc Pellet
Chantal Roume
Original Assignee
Ipsen Pharma Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26233477&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE389388(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR9704837A external-priority patent/FR2762318B1/fr
Priority claimed from FR9803666A external-priority patent/FR2776516B1/fr
Application filed by Ipsen Pharma Biotech filed Critical Ipsen Pharma Biotech
Application granted granted Critical
Publication of ATE389388T1 publication Critical patent/ATE389388T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]
    • Y10T428/2985—Solid-walled microcapsule from synthetic polymer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Peptides Or Proteins (AREA)
AT98921551T 1997-04-18 1998-04-17 Zusammensetzungen mit verzoegerter freisetzung und verfahren zu deren herstellung ATE389388T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9704837A FR2762318B1 (fr) 1997-04-18 1997-04-18 Compositions presentant une liberation prolongee et leur procede de preparation
FR9803666A FR2776516B1 (fr) 1998-03-25 1998-03-25 Compositions presentant une liberation prolongee et leur procede de preparation

Publications (1)

Publication Number Publication Date
ATE389388T1 true ATE389388T1 (de) 2008-04-15

Family

ID=26233477

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98921551T ATE389388T1 (de) 1997-04-18 1998-04-17 Zusammensetzungen mit verzoegerter freisetzung und verfahren zu deren herstellung

Country Status (22)

Country Link
US (2) US6217893B1 (de)
EP (1) EP0980240B1 (de)
JP (1) JP4557312B2 (de)
CN (2) CN1313082C (de)
AR (2) AR012448A1 (de)
AT (1) ATE389388T1 (de)
AU (1) AU741964B2 (de)
BR (1) BR9808933A (de)
CA (1) CA2286575C (de)
CZ (1) CZ297078B6 (de)
DE (1) DE69839264T2 (de)
DK (1) DK0980240T3 (de)
ES (1) ES2303353T3 (de)
HU (1) HUP0004297A2 (de)
IL (1) IL132217A (de)
MY (1) MY118835A (de)
NO (2) NO327999B1 (de)
PL (1) PL196771B1 (de)
PT (1) PT980240E (de)
RU (1) RU2198678C2 (de)
TW (1) TW577759B (de)
WO (1) WO1998047489A1 (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
TW577759B (en) * 1997-04-18 2004-03-01 Ipsen Pharma Biotech Sustained release compositions in the form of microcapsules or implants and the process for their preparation
US6303138B1 (en) 1999-09-17 2001-10-16 Depuy Orthopaedics Endothelin-based compositions for enhancing connective tissue repair
JP2003530838A (ja) * 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
JP2004528089A (ja) * 2001-04-17 2004-09-16 ユニバーシティ・オブ・シェフィールド メラニン細胞刺激ホルモン（ｍｓｈ）を含む生体適合材料および形成方法
CA2446739A1 (en) * 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
CA2446929C (en) * 2001-06-01 2013-04-09 Novartis Ag Orally administering parathyroid hormone and calcitonin
WO2003000156A1 (en) * 2001-06-22 2003-01-03 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
GB0122113D0 (en) * 2001-09-11 2001-10-31 Astrazeneca Ab Composition
AU2002364587A1 (en) * 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
ES2425738T3 (es) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
RU2252753C2 (ru) * 2002-05-15 2005-05-27 Ооо Мако Готовая лекарственная форма инсулина человека пролонгированного действия
NZ539218A (en) * 2002-09-18 2008-03-28 Univ Montreal Ct Hospitalier Chum Synthetic GHRH analogues of 29 amino acids or more
US20040097419A1 (en) * 2002-11-19 2004-05-20 Holger Petersen Organic compounds
WO2004060387A1 (en) * 2002-12-27 2004-07-22 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US7655618B2 (en) * 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
EP1594530A4 (de) 2003-01-22 2006-10-11 Human Genome Sciences Inc Albuminfusionsproteine
CA2519779A1 (en) * 2003-03-26 2004-10-14 Teva Pharmaceutical Industries Ltd. A process for preparing a pharmaceutical active ingredient with high specific surface area
WO2004089279A2 (en) * 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd. Long-acting derivatives of pyy agonists
US20070207211A1 (en) * 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
BRPI0409032A (pt) 2003-04-10 2006-05-02 Pr Pharmaceuticals método para a produção de micropartìculas à base de emulsão
CA2523859C (en) 2003-04-29 2011-08-02 The General Hospital Corporation Methods and devices for the sustained release of multiple drugs
CN102935069A (zh) * 2003-07-15 2013-02-20 Pr药品有限公司 控释组合物的制备方法
US8900636B2 (en) * 2003-07-23 2014-12-02 Evonik Corporation Controlled release compositions
JP2007531513A (ja) * 2003-11-13 2007-11-08 ハンミ ファーム．インダストリー カンパニー リミテッド 薬物のキャリアとして有用なＩｇＧＦｃ断片およびその製造方法
EP2286791B1 (de) * 2003-12-30 2014-03-26 Durect Corporation Polymereimplantate, welche vorzugsweise ein Gemisch von PEG und PLG enthalten, für kontrollierte Freisetzung von Wirkstoffen
EP2368579A1 (de) * 2004-01-21 2011-09-28 Novo Nordisk Health Care AG Tranglutaminase vermittelte konjugation von peptiden.
US20060110423A1 (en) * 2004-04-15 2006-05-25 Wright Steven G Polymer-based sustained release device
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
WO2005110425A1 (en) * 2004-04-15 2005-11-24 Alkermes, Inc. Polymer-based sustained release device
WO2006052468A2 (en) 2004-10-27 2006-05-18 University Of Denver Adrenocorticotropic hormone analogs and related methods
EP1679065A1 (de) * 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Zubereitung mit kontrollierter Freisetzung von Interferon auf PEGT/PBT-Block-Copolymer-Basis
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
AU2006219717B2 (en) * 2005-03-02 2009-05-21 The Secretary Of State For Defence Pharmaceutical composition
US20070106271A1 (en) * 2005-11-09 2007-05-10 Searete Llc, A Limited Liability Corporation Remote control of substance delivery system
KR20130024987A (ko) * 2005-12-22 2013-03-08 노파르티스 아게 옥트레오티드 및 ２종 이상의 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제
MX2008009125A (es) * 2006-01-18 2008-10-23 Qps Llc Composiciones farmaceuticas con estabilidad mejorada.
EP1837014A1 (de) * 2006-03-21 2007-09-26 Hexal Ag Subkutane Implantate welche ein abbau-resistentes Polylactid-Polymer und ein LH-RH Analogon enthalten
PT2359808E (pt) 2006-08-09 2013-08-28 Intarcia Therapeutics Inc Sistemas de entrega osmótica e montagens de pistão
JP2010522196A (ja) * 2007-03-22 2010-07-01 アルカームズ，インコーポレイテッド コアセルベーション工程
ES2402172T3 (es) 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
UA99830C2 (uk) 2007-06-06 2012-10-10 Дебио Ресшерчи Фармасютикю С.А. Фармацевтична композиція з пролонгованим вивільненням, виготовлена з мікрочастинок
US20080317865A1 (en) * 2007-06-20 2008-12-25 Alkermes, Inc. Quench liquids and washing systems for production of microparticles
CN101917969A (zh) * 2008-01-30 2010-12-15 诺瓦提斯公司 包含奥曲肽和三种线形聚丙交酯-共-乙交酯聚合物的缓释制剂
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
EP2341905B2 (de) * 2008-09-04 2023-09-13 Amylin Pharmaceuticals, LLC Formulierungen mit nicht wässrigen trägern und verzögerter freisetzung
EP3735944A1 (de) 2009-09-28 2020-11-11 Intarcia Therapeutics, Inc. Schnelle initiierung und/oder beendigung der verabreichung substantiell stabiler arzneimittel
DK3536333T3 (da) * 2010-01-04 2022-10-24 Mapi Pharma Ltd Depotsystem der omfatter glatirameracetat
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
IT1402654B1 (it) 2010-09-20 2013-09-13 Cid S R L Composizione per il rilascio di principi attivi da dispositivi di impianto
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN103163258B (zh) * 2011-12-09 2015-09-23 山东绿叶制药有限公司 一种测定痕量曲普瑞林的方法
CN102552166A (zh) * 2012-01-09 2012-07-11 北京化工大学 一种溶菌酶/聚(α-氰基丙烯酸异丁酯)载药微球的制备方法
KR20140145140A (ko) * 2012-03-08 2014-12-22 콘세호 수페리오르 데 인베스티가시오네스 시엔티피카스 씨.에스.아이.씨. 광학 용품 및 글레이징 처리한 표면에 도포할 수 있는 포토크로믹성을 갖는 코팅, 이 코팅의 제조 방법 및 그것의 용도
RU2650636C2 (ru) 2012-05-03 2018-04-16 Янссен Сайенсиз Айрлэнд Юси Составы на основе полиинозиновой-полицитидиловой кислоты (poly(i:с)) для лечения инфекций верхних дыхательных путей
RU2506269C1 (ru) * 2012-08-03 2014-02-10 Татьяна Георгиевна Емельянова Фармацевтическая композиция, содержащая физиологически активные гептапептиды, обладающие противосудорожным, анксиолитическим, центральным противовоспалительным и анальгетическим, а также антиалкогольным действием
PL2987484T3 (pl) * 2013-04-18 2019-07-31 Shandong Luye Pharmaceutical Co., Ltd. Kompozycja farmaceutyczna mikrosfery o przedłużonym uwalnianiu gosereliny
CN103230624A (zh) * 2013-05-02 2013-08-07 复旦大学附属上海市第五人民医院 一种用于微创埋线治疗的植入材料
CN103720663B (zh) * 2014-01-08 2016-04-06 昆药集团股份有限公司 一种促卵泡激素缓释微球及其制备方法
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US20160106804A1 (en) * 2014-10-15 2016-04-21 Yuhua Li Pharmaceutical composition with improved stability
KR102650751B1 (ko) 2015-06-03 2024-03-22 인타르시아 세라퓨틱스 인코포레이티드 임플란트 배치 및 제거 시스템들
US10322169B2 (en) * 2015-06-10 2019-06-18 Evonik Roehm Gmbh Process for preparing a powder comprising a human coagulation factor protein and a lactic acid polymer
CN107224571A (zh) * 2016-03-23 2017-10-03 张巍 一种具有坐骨神经保护功能的plga复合微球
ITUA20162094A1 (it) 2016-03-29 2017-09-29 Cid S P A Perfezionamenti negli stent per il rilascio di principi attivi
CN105963258B (zh) 2016-04-26 2021-01-22 广州帝奇医药技术有限公司 一种缓释微粒的制备方法
CN109310743A (zh) 2016-05-16 2019-02-05 因塔西亚制药公司 胰高血糖素受体选择性多肽及其使用方法
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
AU2017319728B2 (en) 2016-08-31 2024-09-05 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
MX2019010174A (es) 2017-03-26 2019-10-15 Mapi Pharma Ltd Sistemas de deposito de glatiramer para el tratamiento de formas progresivas de esclerosis multiple.
CN107375910B (zh) * 2017-07-12 2020-03-24 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 PTHrP在制备治疗男性性腺功能低下综合征中的应用
CN110547969A (zh) * 2019-09-03 2019-12-10 杭州诺泰澳赛诺医药技术开发有限公司 一种高比表面积纳米级缓释微粉的生产工艺及设备
IT202000017191A1 (it) * 2020-07-15 2022-01-15 Xbrane Biopharma Ab Procedimento senza acqua per preparare una composizione farmaceutica per un rilascio più prolungato e controllato di triptorelina o di un suo sale
CN112156170B (zh) * 2020-11-03 2022-10-21 北京康欣东弘医药科技有限公司 可供皮下注射的曲普瑞林缓释微球及其制备方法和用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH661206A5 (fr) * 1983-09-23 1987-07-15 Debiopharm Sa Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes.
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
DE3734223A1 (de) * 1987-10-09 1989-04-20 Boehringer Ingelheim Kg Implantierbares, biologisch abbaubares wirkstofffreigabesystem
US5021554A (en) 1989-02-24 1991-06-04 Eli Lilly And Company Process for protein particle size reduction using a fluid-energy mill
GB9016885D0 (en) * 1990-08-01 1990-09-12 Scras Sustained release pharmaceutical compositions
GB2246514B (en) * 1990-08-01 1993-12-15 Scras Sustained release pharmaceutical compositions and the preparation of particles for use therein
DE4041563A1 (de) 1990-12-22 1992-06-25 Sanol Arznei Schwarz Gmbh Verfahren zur herstellung wirkstoffhaltiger mikropartikel aus hydrolytisch abbaubaren polymeren
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
DE4223169C1 (de) * 1992-07-10 1993-11-25 Ferring Arzneimittel Gmbh Verfahren zur Mikroverkapselung wasserlöslicher Wirkstoffe
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
EP0678018B1 (de) * 1993-01-06 2003-04-09 Kinerton Limited Ionische molekularkonjugate von bioabbaubaren polyestern und bioaktiven polypeptiden
US5785976A (en) * 1993-03-05 1998-07-28 Pharmacia & Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
US6117455A (en) * 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
KR19980703876A (ko) * 1995-04-14 1998-12-05 스티븐 엘. 허스트 분산성이 개선된 분말화된 약학적 조성물
WO1996040072A2 (en) * 1995-06-07 1996-12-19 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of human growth hormone
WO1997026869A1 (en) * 1996-01-24 1997-07-31 United States Government Represented By The Secretary Of The Army Novel 'burst-free' sustained release poly-(lactide/glycolide) microspheres
TW577759B (en) * 1997-04-18 2004-03-01 Ipsen Pharma Biotech Sustained release compositions in the form of microcapsules or implants and the process for their preparation

Also Published As

Publication number Publication date
PL336296A1 (en) 2000-06-19
JP2002500631A (ja) 2002-01-08
DK0980240T3 (da) 2008-07-28
CN1144584C (zh) 2004-04-07
PT980240E (pt) 2008-06-06
AU7436398A (en) 1998-11-13
NO20080803L (no) 1999-11-15
RU2198678C2 (ru) 2003-02-20
JP4557312B2 (ja) 2010-10-06
WO1998047489A1 (fr) 1998-10-29
PL196771B1 (pl) 2008-01-31
AU741964B2 (en) 2001-12-13
AR061828A2 (es) 2008-09-24
EP0980240B1 (de) 2008-03-19
BR9808933A (pt) 2000-08-01
CA2286575C (fr) 2012-06-05
IL132217A (en) 2004-08-31
CZ297078B6 (cs) 2006-09-13
NO995063L (no) 1999-11-15
MY118835A (en) 2005-01-31
US6475507B1 (en) 2002-11-05
DE69839264D1 (de) 2008-04-30
CN1313082C (zh) 2007-05-02
CN1256628A (zh) 2000-06-14
NO995063D0 (no) 1999-10-15
CN1494900A (zh) 2004-05-12
IL132217A0 (en) 2001-03-19
US6217893B1 (en) 2001-04-17
CZ362699A3 (cs) 2000-04-12
HK1027983A1 (en) 2001-02-02
AR012448A1 (es) 2000-10-18
DE69839264T2 (de) 2009-05-14
CA2286575A1 (fr) 1998-10-29
EP0980240A1 (de) 2000-02-23
HUP0004297A2 (hu) 2001-08-28
TW577759B (en) 2004-03-01
ES2303353T3 (es) 2008-08-01
NO327999B1 (no) 2009-11-09

Similar Documents

Publication Publication Date Title
ATE389388T1 (de) Zusammensetzungen mit verzoegerter freisetzung und verfahren zu deren herstellung
DE69818644D1 (de) Silikonzusammensetzungen und verfahren zu deren herstellung
DE69830510D1 (de) Verbundwerkstoffe und verfahren zu deren herstellung
DE69805283D1 (de) Fluorelastomerzusammensetzungen und verfahren zu ihrer herstellung
ATE379971T1 (de) Disinfektionsmittel und verfahren zu dessen herstellung
DE69929311D1 (de) Oximanderivate und verfahren zu ihrer herstellung
ATE279506T1 (de) Tabletten und verfahren zu deren herstellung
DE59806872D1 (de) Leistungshalbleiter-bauelement und verfahren zu dessen herstellung
DE69804217D1 (de) Dekorfolie und verfahren zu deren herstellung
DE69941054D1 (de) Isosorbid enthaltende poyester und verfahren zu deren herstellung
DE69616516D1 (de) Wasserschutzzusammensetzungen und verfahren zu deren herstellung
DE69720523D1 (de) Polyolefin-polyethylenoxid-mischungen und verfahren zu deren herstellung
DE59809806D1 (de) Chemische mikroreaktoren und verfahren zu deren herstellung
DE69529065D1 (de) Härtbare zusammensetzung und verfahren zu ihrer herstellung
DE69636166D1 (de) Klebstoffzusammensetzung und verfahren zu ihrer herstellung
DE59603890D1 (de) Bürste und verfahren zu deren herstellung
DE69922815D1 (de) Gipsplatte und verfahren zu ihrer herstellung
DE69611599D1 (de) Halbaromatische polyamidzusamensetzung und verfahren zu ihrer herstellung
ATE241613T1 (de) Pyrimidinderivate und verfahren zu deren herstellung
DE69932361D1 (de) Trennschicht und verfahren zu deren herstellung
DE69620405D1 (de) Verbesserte polyarylenetherzusammensetzungen und verfahren zu ihrer herstellung
DE69924980D1 (de) Feuerverzögernde konzentrate und verfahren zu deren herstellung
DE69837849D1 (de) Kohlekommutator und verfahren zu dessen herstellung
DE69817337D1 (de) Polypropylenzusammensetzung sowie verfahren zu deren herstellung
DE59814132D1 (de) Alpha 1-antitrypsin-präparation sowie verfahren zu deren herstellung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0980240

Country of ref document: EP